Altri has built on 30 years of research on the insulin-like growth factor (IGF) signaling system to develop agonistic mAbs to use this system for cancer treatment. Altri has licensed the patents for targeting the IGFBP-3/TMEM219 pathway for the treatment of human diseases from Virginia Commonwealth University for all indications globally. Altri’s initial target is directed at TNBC, but Altri plans to use the same antibody therapeutics approach to develop related agonistic mAbs targeting metastatic and invasive cancers including lung, colon, pancreatic and liver cancer, melanoma and leukemia. Altri has also filed additional patents for the protection of the use of agonistic mAbs for other indications including cancer and inflammatory diseases.
STAGE OF BUSINESS: Novel therapeutic antibody drug candidates currently validated in pre-clinical studies, IND-enabling development under preparation. Matching government funding in progress.
IGFBP-3/TMEM219 axis represents a novel anti-tumor and anti-metastatic signaling in TNBC and other cancers including lung, colon, pancreatic and liver cancer, melanoma and leukemia. This novel anti-tumor axis is dysregulated in TNBC mainly owing to the suppression of IGFBP-3, whereas...
Read More TMEM219 anti-tumor signaling remains functional and can be activated by treatment with ALT-101: (1) ALT-101 inhibits growth of TNBC cells but not normal mammary epithelial cells in vitro; (2) ALT-101 induces apoptosis and inhibits migration of TNBC cells only in a TMEM219-dependent manner; (3) ALT-101 inhibits tumor growth and metastasis in orthotopic mouse model and patient derived xenograft (PDX) TNBC models. ALT-101 specifically exerts anti-tumor and anti-metastatic functions in TNBC via induction of apoptosis, suppression of tumor-activated NF-B signaling, inhibition of Bcl-2 family survival proteins, and inhibition of ICAM-1, all tumor-specific factors involved in tumorigenesis and cancer progression.
ALT-1 is efficacious in multiple metastatic cancer models, including TNBC, shrinks primary tumors and prevents their metastatic spreads in preclinical animal tumor models. There is substantial preclinical evidence showing that ALT-101 is an effective therapeutic drug candidate against other tumors.
Exclusive global licenses for targeting the IGFBP-3/TMEM219 pathway for the treatment of human diseases. Altri also filed additional patents for application of the mAbs for other indications including cancer and inflammatory diseases.
The goal is to pursue at least one of these therapeutic candidates towards IND-filing and Phase I/II clinical trials, while other assets continue their pre-clinical development. IND-enabling studies (process development, large-animal...
Read More toxicology and GMP manufacturing) are planned and awaiting further funding. Ready for key go/no-go IND approval of ALT-101 for TNBC in the fourth quarter of 2022 and Phase Ib/II trial of ALT-101 in 2025.
|Lead Discovery||POC/Preclinical||Phase 1||Phase 2/3|
|Th-1 type inflammatory disease|
800 East Leigh St, Suite 1234 Richmond, VA 23219